Cebranopadol is under clinical development by Tris Pharma and currently in Phase II for Pain. According to GlobalData, Phase II drugs for Pain have a 45% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Cebranopadol’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Cebranopadol overview
Cebranopadol (GRT-6005) is under development for the treatment of acute pain, chronic low back pain, chronic neuropathic pain and opioid addiction. It is an orally administered analgesic agent that exhibits a potent agonist activity on opioid receptor like -1 (ORL1) and mu opioid receptor.
It was also under development for the treatment of chronic nociceptive pain and chronic moderate to severe pain related to cancer, chronic pain due to diabetic peripheral neuropathy, post-operative pain in hallux valgus (Bunion), chronic pain due to knee osteoarthritis (OA), addiction, cancer pain and chronic low back pain
Tris Pharma overview
Tris Pharma discovers, develops and commercializes over-the-counter and generic products. The company’s pipeline product candidates include TRN-110, TRN-124, TRN-125, TRN-167, TRN-123, TRN-152, TRN-148, TRN-213, TRN-219, and TRN-226. Its generic products include colesevelam, dexmethylphenidate, dextroamphetamine, doxycycline Hyclate, doxycycline hyclate, droxidopa, febuxostat, hydrocodone, hydrocodone polistirex, lacosamide, methylphenidate, morphine sulfate and paliperidone ER. Tris Pharma is headquartered in South Brunswick, New Jersey, the US.
For a complete picture of Cebranopadol’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
